Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice

Min Wu, Sahn Ho Kim, Indrani Datta, Albert Levin, Gregory Dyson, Jing Li, Stephanie Kaypee, M. Mahadeva Swamy, Nilesh Gupta, Ho Jeong Kwon, Mani Menon, Tapas K. Kundu, G. Prem Veer Reddy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

There is a critical need for therapeutic agents that can target the amino-terminal domain (NTD) of androgen receptor (AR) for the treatment of castration-resistant prostate cancer (CRPC). Calmodulin (CaM) binds to the AR NTD and regulates AR activity. We discovered that Hydrazinobenzoylcurcumin (HBC), which binds exclusively to CaM, inhibited AR activity. HBC abrogated AR interaction with CaM, suppressed phosphorylation of AR Serine81, and blocked the binding of AR to androgen-response elements. RNA-Seq analysis identified 57 androgen-regulated genes whose expression was significantly (p ≤ 0.002) altered in HBC treated cells as compared to controls. Oncomine analysis revealed that genes repressed by HBC are those that are usually overexpressed in prostate cancer (PCa) and genes stimulated by HBC are those that are often down-regulated in PCa, suggesting a reversing effect of HBC on androgenregulated gene expression associated with PCa. Ingenuity Pathway Analysis revealed a role of HBC affected genes in cellular functions associated with proliferation and survival. HBC was readily absorbed into the systemic circulation and inhibited the growth of xenografted CRPC tumors in nude mice. These observations demonstrate that HBC inhibits AR activity by targeting the AR NTD and suggest potential usefulness of HBC for effective treatment of CRPC.

Original languageEnglish
Pages (from-to)6136-6150
Number of pages15
JournalOncotarget
Volume6
Issue number8
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Castration
Androgen Receptors
Prostatic Neoplasms
Growth
Calmodulin
Androgens
hydrazinobenzoylcurcumin
Gene Expression
Neoplasm Genes
Response Elements
Nude Mice
Genes
Phosphorylation
RNA

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Wu, Min ; Kim, Sahn Ho ; Datta, Indrani ; Levin, Albert ; Dyson, Gregory ; Li, Jing ; Kaypee, Stephanie ; Mahadeva Swamy, M. ; Gupta, Nilesh ; Kwon, Ho Jeong ; Menon, Mani ; Kundu, Tapas K. ; Reddy, G. Prem Veer. / Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice. In: Oncotarget. 2015 ; Vol. 6, No. 8. pp. 6136-6150.
@article{765f870d6eec42588a3efc77d171c263,
title = "Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice",
abstract = "There is a critical need for therapeutic agents that can target the amino-terminal domain (NTD) of androgen receptor (AR) for the treatment of castration-resistant prostate cancer (CRPC). Calmodulin (CaM) binds to the AR NTD and regulates AR activity. We discovered that Hydrazinobenzoylcurcumin (HBC), which binds exclusively to CaM, inhibited AR activity. HBC abrogated AR interaction with CaM, suppressed phosphorylation of AR Serine81, and blocked the binding of AR to androgen-response elements. RNA-Seq analysis identified 57 androgen-regulated genes whose expression was significantly (p ≤ 0.002) altered in HBC treated cells as compared to controls. Oncomine analysis revealed that genes repressed by HBC are those that are usually overexpressed in prostate cancer (PCa) and genes stimulated by HBC are those that are often down-regulated in PCa, suggesting a reversing effect of HBC on androgenregulated gene expression associated with PCa. Ingenuity Pathway Analysis revealed a role of HBC affected genes in cellular functions associated with proliferation and survival. HBC was readily absorbed into the systemic circulation and inhibited the growth of xenografted CRPC tumors in nude mice. These observations demonstrate that HBC inhibits AR activity by targeting the AR NTD and suggest potential usefulness of HBC for effective treatment of CRPC.",
author = "Min Wu and Kim, {Sahn Ho} and Indrani Datta and Albert Levin and Gregory Dyson and Jing Li and Stephanie Kaypee and {Mahadeva Swamy}, M. and Nilesh Gupta and Kwon, {Ho Jeong} and Mani Menon and Kundu, {Tapas K.} and Reddy, {G. Prem Veer}",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.3346",
language = "English",
volume = "6",
pages = "6136--6150",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "8",

}

Wu, M, Kim, SH, Datta, I, Levin, A, Dyson, G, Li, J, Kaypee, S, Mahadeva Swamy, M, Gupta, N, Kwon, HJ, Menon, M, Kundu, TK & Reddy, GPV 2015, 'Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice', Oncotarget, vol. 6, no. 8, pp. 6136-6150. https://doi.org/10.18632/oncotarget.3346

Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice. / Wu, Min; Kim, Sahn Ho; Datta, Indrani; Levin, Albert; Dyson, Gregory; Li, Jing; Kaypee, Stephanie; Mahadeva Swamy, M.; Gupta, Nilesh; Kwon, Ho Jeong; Menon, Mani; Kundu, Tapas K.; Reddy, G. Prem Veer.

In: Oncotarget, Vol. 6, No. 8, 01.01.2015, p. 6136-6150.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice

AU - Wu, Min

AU - Kim, Sahn Ho

AU - Datta, Indrani

AU - Levin, Albert

AU - Dyson, Gregory

AU - Li, Jing

AU - Kaypee, Stephanie

AU - Mahadeva Swamy, M.

AU - Gupta, Nilesh

AU - Kwon, Ho Jeong

AU - Menon, Mani

AU - Kundu, Tapas K.

AU - Reddy, G. Prem Veer

PY - 2015/1/1

Y1 - 2015/1/1

N2 - There is a critical need for therapeutic agents that can target the amino-terminal domain (NTD) of androgen receptor (AR) for the treatment of castration-resistant prostate cancer (CRPC). Calmodulin (CaM) binds to the AR NTD and regulates AR activity. We discovered that Hydrazinobenzoylcurcumin (HBC), which binds exclusively to CaM, inhibited AR activity. HBC abrogated AR interaction with CaM, suppressed phosphorylation of AR Serine81, and blocked the binding of AR to androgen-response elements. RNA-Seq analysis identified 57 androgen-regulated genes whose expression was significantly (p ≤ 0.002) altered in HBC treated cells as compared to controls. Oncomine analysis revealed that genes repressed by HBC are those that are usually overexpressed in prostate cancer (PCa) and genes stimulated by HBC are those that are often down-regulated in PCa, suggesting a reversing effect of HBC on androgenregulated gene expression associated with PCa. Ingenuity Pathway Analysis revealed a role of HBC affected genes in cellular functions associated with proliferation and survival. HBC was readily absorbed into the systemic circulation and inhibited the growth of xenografted CRPC tumors in nude mice. These observations demonstrate that HBC inhibits AR activity by targeting the AR NTD and suggest potential usefulness of HBC for effective treatment of CRPC.

AB - There is a critical need for therapeutic agents that can target the amino-terminal domain (NTD) of androgen receptor (AR) for the treatment of castration-resistant prostate cancer (CRPC). Calmodulin (CaM) binds to the AR NTD and regulates AR activity. We discovered that Hydrazinobenzoylcurcumin (HBC), which binds exclusively to CaM, inhibited AR activity. HBC abrogated AR interaction with CaM, suppressed phosphorylation of AR Serine81, and blocked the binding of AR to androgen-response elements. RNA-Seq analysis identified 57 androgen-regulated genes whose expression was significantly (p ≤ 0.002) altered in HBC treated cells as compared to controls. Oncomine analysis revealed that genes repressed by HBC are those that are usually overexpressed in prostate cancer (PCa) and genes stimulated by HBC are those that are often down-regulated in PCa, suggesting a reversing effect of HBC on androgenregulated gene expression associated with PCa. Ingenuity Pathway Analysis revealed a role of HBC affected genes in cellular functions associated with proliferation and survival. HBC was readily absorbed into the systemic circulation and inhibited the growth of xenografted CRPC tumors in nude mice. These observations demonstrate that HBC inhibits AR activity by targeting the AR NTD and suggest potential usefulness of HBC for effective treatment of CRPC.

UR - http://www.scopus.com/inward/record.url?scp=84925680035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925680035&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.3346

DO - 10.18632/oncotarget.3346

M3 - Article

C2 - 25704883

AN - SCOPUS:84925680035

VL - 6

SP - 6136

EP - 6150

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 8

ER -